Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655019 | 0.94 | HDAC1 (0.44) | CYP1A2HDAC6HDAC1HDAC2DNM1 | |
| SCHEMBL499027 | 0.90 | SMN1; SMN2 (0.40) | CYP1A2HDAC6HDAC1HDAC2DNM1 | |
| SCHEMBL10042565 | 0.87 | CA12 (0.40) | CYP1A2HDAC6HDAC1HDAC2ALOX5 | |
| SCHEMBL23477345 | 0.85 | HDAC6 (0.39) | HDAC6HDAC1HDAC2DNM1ALDH1A1 | |
| SCHEMBL2020494 | 0.83 | TSHR (0.47) | HDAC6HDAC1HDAC2CA12CA1 | |
| SCHEMBL23777414 | 0.83 | ALDH1A1 (0.47) | HDAC6HDAC1HDAC2DNM1CA12 | |
| SCHEMBL21997123 | 0.82 | CA12 (0.34) | CYP1A2HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL9227134 | 0.81 | HDAC6 (0.46) | HDAC6HDAC1HDAC2ALDH1A1L3MBTL1 | |
| SCHEMBL14528134 | 0.81 | CYP1A2 (0.35) | CYP1A2HDAC6HDAC1HDAC2ALOX5 | |
| SCHEMBL31462534 | 0.81 | GAA (0.41) | CYP1A2HDAC6HDAC1HDAC2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434753-B2 | Modified creatine compounds | GENCIA CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150005258-A1 | Modified Creatine Compounds | Genci Corporation (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2013043580-A2 | MODIFIED CREATINE COMPOUNDS | GENCIA CORPORATION (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005258-A1 | Modified Creatine Compounds | CKMT1A; CKMT1B, SLC25A20, ARG2 | CYP1A2 3817/4885HDAC6 1363/4885HDAC1 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.